Page last updated: 2024-12-06

2-(2-pyridyl)ethylidine-1,1-bisphosphonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 2-(2-Pyridyl)ethylidine-1,1-bisphosphonate: A Novel Antiviral Agent

**2-(2-Pyridyl)ethylidine-1,1-bisphosphonate**, also known as **PEB**, is a synthetic organic compound with a unique structure containing a pyridine ring and a bisphosphonate group. It's gaining significant attention in research due to its potential as an antiviral agent.

**Here's why it's important for research:**

* **Antiviral Activity:** PEB has demonstrated antiviral activity against various viruses, including **HIV**, **Hepatitis C virus (HCV)**, and **influenza virus**. This is due to its ability to inhibit the replication of these viruses by targeting specific viral enzymes or proteins involved in the viral life cycle.
* **Mechanism of Action:** The exact mechanism of action of PEB varies depending on the virus it's targeting. For instance, in the case of HIV, it has been shown to inhibit the **integrase enzyme**, which is crucial for integrating the viral DNA into the host's genome. This inhibition effectively blocks the virus from replicating and spreading.
* **Potent and Selective:** PEB exhibits high potency against certain viruses while maintaining a relatively low toxicity profile. This suggests it could be a promising candidate for developing new antiviral therapies.
* **Novel Structure:** The unique combination of the pyridine ring and bisphosphonate group in PEB distinguishes it from other antiviral compounds. This novel structure provides opportunities for developing new antiviral agents with improved efficacy and safety profiles.

**Ongoing research:**

* Scientists are actively investigating the antiviral efficacy of PEB against other viruses and exploring its potential as a treatment for various viral infections.
* Efforts are underway to optimize the structure and delivery methods of PEB to enhance its antiviral activity and reduce potential side effects.
* Preclinical studies are being conducted to evaluate the safety and efficacy of PEB in animal models before potential human clinical trials.

**Overall, 2-(2-Pyridyl)ethylidine-1,1-bisphosphonate (PEB) holds immense promise as a novel antiviral agent due to its potent activity, selectivity, and unique chemical structure. Ongoing research efforts are paving the way for the development of new and effective antiviral therapies based on this promising compound.**

2-(2-pyridyl)ethylidine-1,1-bisphosphonate: inhibits hypercalciuria [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID57637
CHEMBL ID99369
SCHEMBL ID223779
MeSH IDM0153256

Synonyms (23)

Synonym
CHEMBL99369 ,
[1-phosphono-2-(pyridin-2-yl)ethyl]phosphonic acid
ne97221
gtpl3183
piridronic acid
(1-phosphono-2-pyridin-2-ylethyl)phosphonic acid
add4h8t3k9 ,
acido piridronico [spanish]
acide piridronique
75755-07-6
phosphonic acid, (2-(2-pyridinyl)ethylidene)bis-
2-(2-pyridyl)ethylidine-1,1-bisphosphonate
acidum piridronicum
acido piridronico
(2-(2-pyridyl)ethylidene)diphosphonic acid
acide piridronique [french]
piridronic acid [inn]
unii-add4h8t3k9
acidum piridronicum [latin]
bdbm50373096
SCHEMBL223779
DTXSID50226652
Q27088401

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Rats were dosed concomitantly with indomethacin (40 mg/kg, subcutaneously) and an amino or pyridinyl bisphosphonate (orally at."( Nonclinical model for assessing gastric effects of bisphosphonates.
Berman, SK; Blank, MA; Ems, BL; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Farnesyl pyrophosphate synthaseHomo sapiens (human)IC50 (µMol)0.14460.00020.71099.3600AID318593; AID318594
Farnesyl pyrophosphate synthaseHomo sapiens (human)Ki0.02170.00010.21651.9000AID318593; AID318594
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
cholesterol biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
geranyl diphosphate biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
farnesyl diphosphate biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
RNA bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
protein bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
metal ion bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
dimethylallyltranstransferase activityFarnesyl pyrophosphate synthaseHomo sapiens (human)
geranyltranstransferase activityFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleoplasmFarnesyl pyrophosphate synthaseHomo sapiens (human)
cytosolFarnesyl pyrophosphate synthaseHomo sapiens (human)
cytoplasmFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID318594Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID318595Inhibition of bone resorption in rat assessed as phosphate2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID318593Inhibition of human recombinant FPPS expressed in Escherichia coli BL212008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID184809Bone resorption activity in rats.2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
AID55429Ability to inhibit growth of Dictostelium discoideum.2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's3 (50.00)18.2507
2000's2 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.69 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]